Mydoflex (Tolperisone Hydrochloride)

Tolperisone Hydrochloride acts on the central nervous system by blocking voltage‑gated sodium channels in spinal neurons. This inhibition reduces the excitability of reflex pathways, leading to decreased spinal reflex activity and lower muscle tone, which alleviates spasticity and painful muscle contractions.

The specific dose of Mydoflex is determined by the prescribing clinician based on the individual’s condition, severity, age, and renal or hepatic function. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety data for Tolperisone Hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mydoflex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other central muscle relaxants such as baclofen or tizanidine, Tolperisone Hydrochloride has a distinct mechanism—blocking sodium channels rather than acting on GABA‑B receptors. This may result in a different side‑effect profile, often with lower sedation, but clinical choice depends on individual patient response and tolerability.

Mydoflex should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mydoflex is taken orally, usually with a glass of water. The tablet (or other oral form) should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse reactions, though rare, can include severe skin reactions such as Stevens‑Johnson syndrome, significant liver enzyme elevations indicating hepatic injury, and blood dyscrasias like agranulocytosis. Patients should seek immediate medical attention if they notice rash, jaundice, or signs of infection.

Mydoflex is contraindicated in patients with known hypersensitivity to Tolperisone Hydrochloride or any excipients in the formulation. Caution is also advised for individuals with severe hepatic or renal impairment, and it should be avoided in combination with other central muscle relaxants without medical supervision.